Similar articles

• Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

  Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS. Eron JJ, et al. AIDS. 2000 Apr 14;14(6):671-81. doi: 10.1097/00002030-200004140-00006. AIDS. 2000. PMID: 10807190 Clinical Trial.
• Double protease inhibitor regimens with amprenavir show promise.

  [No authors listed] [No authors listed] AIDS Patient Care STDS. 1998 Apr;12(4):317-8. AIDS Patient Care STDS. 1998. PMID: 11361962 No abstract available.
• Amprenavir study results released.

  [No authors listed] [No authors listed] AIDS Patient Care STDS. 1999 Dec;13(12):754. AIDS Patient Care STDS. 1999. PMID: 10743545 No abstract available.
• Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.

  Keiser P, Nassar N. Keiser P, et al. Expert Opin Pharmacother. 2007 Mar;8(4):477-83. doi: 10.1517/14656566.8.4.477. Expert Opin Pharmacother. 2007. PMID: 17309342 Review.
• Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.

  Spooner KM, Lane HC, Masur H. Spooner KM, et al. Clin Infect Dis. 1996 Jul;23(1):15-27. doi: 10.1093/clinids/23.1.15. Clin Infect Dis. 1996. PMID: 8816123 Review. No abstract available.